Optical ray tracing

Customised excimer LASIK ablations currently rely on corneal topography or whole-eye wavefront technology. However, critics note that these fail to consider the multiple lens structure of the eye and fail to address all optical errors of the eye, resulting in a clinical outcome that may be poorer than expected. A new study suggests that optical ray tracing may be the next step in custom ablation. Researchers conducted a multicentre study of 127 eyes with moderate to high myopic astigmatism that underwent custom LASIK ablation based on a new optical ray-tracing algorithm. Approximately 84 per cent of 111 eyes available for follow-up at three months postoperatively had uncorrected distance acuity of at least 20/20. All were within 1 D of the intended correction, with 96 per cent within 0.5 D. Uncorrected distance visual acuity in eyes treated for high myopic astigmatism was better than in those undergoing wavefront-guided LASIK. The researchers conclude that the new system, which does not require a nomogram, is safe, efficacious and predictable.
S Schumacher, JCRS, Optical ray tracing-guided laser in situ keratomileusis for moderate to high myopic astigmatism, Volume 38, Issue 1, pages 28-34.
Latest Articles
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.